The present disclosure is in the field of diagnostics and therapeutics for Alzheimer's Disease.

A method of reducing the appearance of skin redness is disclosed. The method can include topically applying to reddened skin an effective amount of a composition that includes a water soluble Phoenix dactylifera seed extract, an essential oil from the leaves of tea tree, an aqueous Myrothamnus flabellifolia leaf and stem extract, and a saccharide isomerate comprising an exopolysaccharide of Vibrio alginolyticus, wherein the appearance of skin redness is reduced.

A method of reducing the appearance of skin redness is disclosed. The method can include topically applying to reddened skin an effective amount of a composition that includes a water soluble Phoenix dactylifera seed extract, an essential oil from the leaves of tea tree, an aqueous Myrothamnus flabellifolia leaf and stem extract, and a saccharide isomerate comprising an exopolysaccharide of Vibrio alginolyticus, wherein the appearance of skin redness is reduced.

A method is provided for lowering blood sugar in a subject in need thereof by administering a gliflozin Sodium-Glucose Cotransport 2 inhibitor pharmaceutical composition to a subject qualified for over-the-counter access to the gliflozin Sodium-Glucose Cotransport 2 inhibitor pharmaceutical composition. In some embodiments, the gliflozin Sodium-Glucose Cotransport 2 inhibitor pharmaceutical composition includes empagliflozin, canagliflozin, and ertugliflozin. In some embodiments, the gliflozin Sodium-Glucose Cotransport 2 inhibitor pharmaceutical composition includes (2S,3R,4R,5S,6R)-2-[4-chloro-3-[(4-ethoxyphenyl)methyl]phenyl]-6-(hydroxymethyl)oxane-3,4,5-triol or a pharmaceutically acceptable salt thereof.

A method is provided for lowering blood sugar in a subject in need thereof by administering a gliflozin Sodium-Glucose Cotransport 2 inhibitor pharmaceutical composition to a subject qualified for over-the-counter access to the gliflozin Sodium-Glucose Cotransport 2 inhibitor pharmaceutical composition. In some embodiments, the gliflozin Sodium-Glucose Cotransport 2 inhibitor pharmaceutical composition includes empagliflozin, canagliflozin, and ertugliflozin. In some embodiments, the gliflozin Sodium-Glucose Cotransport 2 inhibitor pharmaceutical composition includes (2S,3R,4R,5S,6R)-2-[4-chloro-3-[(4-ethoxyphenyl)methyl]phenyl]-6-(hydroxymethyl)oxane-3,4,5-triol or a pharmaceutically acceptable salt thereof.

The present disclosure relates to a stable anti-PD-1 antibody pharmaceutical formulation and a method for preparing the same, the pharmaceutical formulation comprising: an anti-PD-1 antibody or an antigen binding fragment thereof; and a stabilizer, and not comprising a buffer.

The present disclosure relates to a stable anti-PD-1 antibody pharmaceutical formulation and a method for preparing the same, the pharmaceutical formulation comprising: an anti-PD-1 antibody or an antigen binding fragment thereof; and a stabilizer, and not comprising a buffer.

Disclosed herein are methods and compositions for treatment of a microbiome associated disorder. Further, disclosed herein are methods and compositions for modulating short chain fatty acid production in a subject.

Disclosed herein are methods and compositions for treatment of a microbiome associated disorder. Further, disclosed herein are methods and compositions for modulating short chain fatty acid production in a subject.

The invention relates to a novel glucose polymer which is particularly useful for administration by the parenteral route, and to the method for the production thereof. The invention also relates to compositions comprising such a glucose polymer, and to the methods for the production thereof. The invention further relates to the use thereof as a medicament, for example as an osmotic agent for peritoneal dialysis.